Search results for "Remission Induction"

showing 10 items of 141 documents

Beclomethasone dipropionate in Crohn's ileitis: A randomised, double-blind trial.

2011

Abstract Background Steroids, the mainstay of Crohn's disease treatment, have been associated with systemic side effects. Aim To evaluate the efficacy and tolerability of beclomethasone dipropionate for maintaining remission induced by a short course of systemic steroids in patients with Crohn's ileitis with or without right colonic involvement. Methods Patients (n = 84) with active Crohn's disease who achieved remission during a 2-week prednisone run-in period were randomised to receive beclomethasone dipropionate for 24 weeks or continue prednisone for a further 2 weeks followed by placebo for 22 weeks. The primary outcome was relapse rate (Crohn's Disease Activity Index score > 150 and a…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaRemissionKaplan-Meier EstimateBeclomethasone dipropionate Crohn's disease RemissionPlaceboGastroenterologyDrug Administration ScheduleMedication Adherencelaw.inventionDouble blindCrohn DiseaseDouble-Blind MethodRandomized controlled triallawPrednisoneInternal medicineSecondary PreventionmedicineHumansIleitisAdverse effectGlucocorticoidsAgedCrohn's diseaseHepatologybusiness.industryRemission InductionBeclomethasoneGastroenterologyBeclomethasone dipropionate Crohn's ileitis:.Middle Agedmedicine.diseaseSurgeryBeclomethasone dipropionateCrohn's diseaseTreatment OutcomeTolerabilityPrednisoneFemaleTablets Enteric-Coatedbusinessmedicine.drug
researchProduct

Duration of immunosuppressive therapy in autoimmune hepatitis

2001

AdultMalemedicine.medical_specialtyTime FactorsAdolescentmedicine.drug_classmedicine.medical_treatmentMEDLINEAutoimmune hepatitisGastroenterologyRemission inductionRecurrenceInternal medicinemedicineHumansChildAgedAutoimmune diseaseHepatitisChemotherapyHepatologybusiness.industryRemission InductionMiddle Agedmedicine.diseaseHepatitis AutoimmuneImmunologyCorticosteroidFemalebusinessImmunosuppressive AgentsJournal of Hepatology
researchProduct

Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study

2016

AIM To evaluate the real-world effectiveness of golimumab in ulcerative colitis (UC) and to identify predictors of response. METHODS We conducted an observational, prospective and multi-center study in UC patients treated with golimumab, from September 2014 to September 2015. Clinical activity was assessed at wk 0 and 14 with the physician' s global clinical assessment (PGA) and the partial Mayo score. Colonoscopies and blood tests were performed, following daily-practice clinical criteria, and the results were recorded in an SPSS database. RESULTS Thirty-three consecutive patients with moderately to severely active UC were included. Among them, 54.5% were female and 42 years was the averag…

AdultMalemedicine.medical_specialtyTime FactorsAnti-Inflammatory AgentsObservational StudySeverity of Illness IndexGolimumab03 medical and health sciences0302 clinical medicineGastrointestinal AgentsAdrenal Cortex HormonesInternal medicineHumansMedicineProspective StudiesTumor Necrosis Factor-alphabusiness.industryRemission InductionGastroenterologyAntibodies MonoclonalColonoscopyGeneral MedicineMiddle Agedmedicine.diseaseReal-life resultsUlcerative colitisdigestive system diseasesGolimumabTreatment OutcomeMulticenter studyUlcerative colitisSpain030220 oncology & carcinogenesisColitis UlcerativeDrug Therapy CombinationFemale030211 gastroenterology & hepatologyObservational studybusinessmedicine.drug
researchProduct

Adalimumab efficacy in enteropathic spondyloarthritis: A 12-mo observational multidisciplinary study

2017

AIM To report adalimumab (Ada) efficacy on articular-gastrointestinal disease and health-related quality of life (HRQoL) in patients with enteropathic spondyloarthritis (ES). METHODS A cohort of 52 patients with ES was evaluated in the departments of gastroenterology and internal medicine. At baseline, all patients underwent assessment by an integrated gastro-rheumatologic evaluation of articular and gastrointestinal activity, as well patient reported outcomes (PROs) of the HRQoL questionnaires. After this integrated evaluation and following a specific working flowchart, the Ada anti-tumor necrosis factor (TNF)-inhibitor was assigned to a cohort of 30 patients and its clinical efficacy was …

AdultMalemedicine.medical_specialtyTime FactorsTumor necrosis factor-inhibitorMultidisciplinary studyObservational StudyInflammatory bowel diseasesInflammatory bowel diseaseWorkflowEnteropathic spondyloarthriti03 medical and health sciences0302 clinical medicineCrohn DiseaseClinimetric assessmentInternal medicineSpondylarthritisTumor necrosis factor-inhibitorsAdalimumabHumansMedicinePatient Reported Outcome MeasuresPatient reported outcomes030203 arthritis & rheumatologyBiological ProductsTumor Necrosis Factor-alphabusiness.industryRemission InductionAdalimumabGastroenterologyInflammatory Bowel DiseasesGeneral MedicineMiddle AgedPatient reported outcomeEnteropathic spondyloarthritisClinimetric assessment; Enteropathic spondyloarthritis; Inflammatory bowel diseases; Multidisciplinary evaluation; Patient reported outcomes; Tumor necrosis factor-inhibitors; GastroenterologyTreatment OutcomeMultidisciplinary evaluationAntirheumatic AgentsCritical PathwaysQuality of LifeColitis UlcerativeFemale030211 gastroenterology & hepatologyObservational studybusinessmedicine.drug
researchProduct

The fate of patients with locally advanced bladder cancer treated conservatively with neoadjuvant chemotherapy, extensive transurethral resection and…

1998

Purpose: We assess the results of bladder preservation for infiltrating bladder cancer. The potential for neoadjuvant chemotherapy followed by extensive transurethral resection and radiotherapy was evaluated in 40 patients with T2-T4a G2-G3 bladder carcinoma. Materials and Methods: From 1983 to 1995, 40 patients with bladder cancer underwent bladder sparing treatment, consisting of neoadjuvant chemotherapy, extensive transurethral resection and radiotherapy. Most patients had T3G3 cancer. A deep transurethral resection biopsy was performed before and after chemotherapy, and an extensive transurethral resection was repeated at the end of radiotherapy. Of the patients 30 received cisplatin an…

AdultMalemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentBladderUrologyTransitional cellSettore MED/24 - UrologiaCystectomyCarcinomaMedicineHumansAgedNeoplasm StagingAged 80 and overCarcinoma Transitional CellUrinary bladderBladder cancerRadiotherapybusiness.industryRemission InductionCarcinomaCancerMiddle Agedmedicine.diseaseVinblastineSurgeryRadiation therapyTransitional cell carcinomamedicine.anatomical_structureUrinary Bladder NeoplasmsChemotherapy AdjuvantFemaleDrug therapybusinessmedicine.drugFollow-Up Studies
researchProduct

Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes.

2005

: Background: Splenic marginal zone lymphoma (SMZL) is an infrequent B-cell neoplasm that pursues an indolent course. Signs and symptoms, mostly related to hypersplenism, are successfully managed by splenectomy. However, the therapy of patients who are not fit for a surgical procedure or who relapse after splenectomy, is still an unsettled issue. Patients and methods: We report a phase-II study on 16 patients with SMZL, three therapy naive and 13 pretreated, all showing systemic symptoms or progressive worsening of peripheral cytopenia, who were treated with pentostatin at a dose of 4 mg/m2 every other week for 6–10 wk. In relapsed patients, the median interval between diagnosis and treatme…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentSplenectomyPurine analogueDrug Administration SchedulemedicinePentostatinHumansProgression-free survivalSplenic marginal zone lymphomaLymphocytesAgedCytopeniaDeoxycoformycinbusiness.industrySplenic NeoplasmsRemission InductionNeoplasms Second PrimaryHematologyGeneral MedicineLymphoma B-Cell Marginal ZoneMiddle Agedmedicine.diseaseSMZLSurvival AnalysisSurgerysplenic marginal zonelymphomaDeoxycoformycinFemaleSplenic LymphomabusinessPentostatinvillous lymphocytesmedicine.drugEuropean journal of haematology
researchProduct

Sustained Complete Molecular Remissions After Treatment With Imatinib-Mesylate in Patients With Failure After Allogeneic Stem Cell Transplantation fo…

2005

Purpose In the era of molecular therapy of chronic myelogenous leukemia (CML) applying BCR-ABL tyrosine kinase inhibitors, the usefulness of molecular end points, in particular, quantitative polymerase chain reaction (PCR) for BCR-ABL in monitoring responses has been broadly accepted. Therefore, we have designed a prospective phase II trial in CML, which, for the first time, evaluated the feasibility and safety of molecular end points as surrogate markers to guide through a stratified treatment algorithm within a multicenter trial. Patients and Methods As a clinical model, we adopted minimal residual disease (MRD) found in relapse after allogeneic stem cell transplantation (SCT) in CML. For…

AdultOncologyCancer Researchmedicine.medical_specialtyTime FactorsMaximum Tolerated Dosemedicine.drug_classFusion Proteins bcr-ablGraft vs Host DiseaseAntineoplastic AgentsPolymerase Chain ReactionPiperazinesTyrosine-kinase inhibitorMyelogenousLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesMulticenter trialInternal medicinemedicineHumansTransplantation HomologousProspective Studiesbusiness.industryRemission InductionImatinibProtein-Tyrosine Kinasesmedicine.diseaseMinimal residual diseaseTransplantationPyrimidinesTreatment OutcomeImatinib mesylateOncologyBenzamidesImmunologyImatinib MesylateFeasibility StudiesbusinessStem Cell Transplantationmedicine.drugChronic myelogenous leukemiaJournal of Clinical Oncology
researchProduct

Rituximab in refractory pemphigus vulgaris

2008

Pemphigus vulgaris (PV) is a severe chronic autoimmune blistering disease of skin and mucous membranes. The use of systemic corticosteroids in pemphigus has dramatically reduced its mortality rate, but the long-term use of steroids leads to severe side effects, many of which are serious. For this reason it is often necessary to add immunosuppressive agents to the regimen. However, there are occasional refractory cases in which therapy with conventionally accepted modalities is either not efficacious or not possible on account of side effects. Rituximab is a therapeutic monoclonal antibody targeting CD20, an integral membrane protein highly expressed on the surface of pre-B lymphocytes and a…

Adultmedicine.medical_specialtyAntigens CD19B-Lymphocyte SubsetsDrug ResistanceDermatologyDrug Administration ScheduleAntibodies Monoclonal Murine-DerivedPharmacotherapyRefractoryRituximab pemphigus vulgarisimmune system diseasesHumansImmunologic FactorsMedicineInfusions IntravenousCD20integumentary systembiologybusiness.industryRemission InductionPemphigus vulgarisAntibodies MonoclonalGeneral MedicineAntigens CD20medicine.diseaseDermatologyRegimenPemphigusMonoclonalImmunologybiology.proteinPrednisoneDrug Therapy CombinationFemaleRituximabRituximabbusinessImmunosuppressive AgentsPemphigusmedicine.drugDermatologic Therapy
researchProduct

Clinical comparison of extracorporeal piezoelectric lithotripsy (EPL) and intracorporeal electrohydraulic lithotripsy (EHL) in difficult bile duct st…

1995

Today, nearly 90% of common bile duct stones are extracted endoscopically. Problems are encountered if there are large stones or a duct stenosis. Extracorporeal piezoelectric lithotripsy (EPL) as well as intracorporeal electrohydraulic lithotripsy (EHL) serve as an alternative to surgical intervention for those few patients in whom endoscopic measures have failed. A total of 35 patients with common bile duct stones in whom conventional endoscopic treatment had failed were selected on the condition that stone visualization through ultrasound was possible and that the papilla was within easy reach of the endoscope. Patients fulfilling the inclusion criteria were randomly treated either by EPL…

Adultmedicine.medical_specialtyPhysiologymedicine.medical_treatmentGallstonesLithotripsyExtracorporealLithotripsymedicineHumansProspective StudiesTreatment FailureAgedAged 80 and overCommon bile ductBile ductbusiness.industryRemission InductionGastroenterologyMiddle AgedExtracorporeal shock wave lithotripsyLaser lithotripsySurgeryMajor duodenal papillamedicine.anatomical_structureBiliary tractbusinessDigestive diseases and sciences
researchProduct

Influence of the ovary on parameters of LH secretion during the recovery from buserelin-induced desensitization

1994

Abstract This study examined the effect of the ovary on LH pulsatility and on the secretory performance of gonadotrophes during the phase of recovery after treatment with buserelin, a GnRH analogue. We included 12 patients, who received buserelin (1.2 mg/day, intranasally for 3 months) as a reductive therapy for uterine leiomyomatosis prior to hysterectomy. Six patients were oophorectomized and the other 6 patients had their ovaries preserved. LH was measured in samples taken basally up to 36 days after suppression of buserelin. LH pulsatility was studied on day 9 along a 24-h cycle, and the response of the hormone to a double-stimulus GnRH test on days 0, 9, 20, and 34. The concentration o…

Adultmedicine.medical_specialtymedicine.drug_classOvariectomymedicine.medical_treatmentRadioimmunoassayUterusEndogenyHysterectomyBuserelinLeiomyomatosisInternal medicinemedicineHumansAdministration IntranasalHysterectomybusiness.industryOvaryRemission InductionObstetrics and GynecologyOophorectomyLuteinizing HormoneMiddle AgedBuserelinEndocrinologymedicine.anatomical_structurePremenopauseReproductive MedicineIn uteroUterine NeoplasmsFemaleGonadotropinbusinessmedicine.drugHormoneEuropean Journal of Obstetrics & Gynecology and Reproductive Biology
researchProduct